stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) EV/FCF
As of 6 November 2026, ACADIA Pharmaceuticals Inc. (ACAD) trades at a EV/FCF of −23.2×. Over the past ten years it has ranged from −198× (January 2024) to 60,792× (December 2025); the current reading is higher than 42% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −39.5× | — |
| FY2024 | 19.5× | — |
| FY2023 | −198× | — |
| FY2022 | −19.3× | — |
| FY2021 | −25.4× | — |
| FY2020 | −54.1× | — |
| FY2019 | −36.8× | — |
| FY2018 | −9.3× | — |
| FY2017 | −15.5× | — |
| FY2016 | −13.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −21.6× | — |
| Jun 2026 | −65.0× | — |
| Mar 2026 | −35.0× | — |
| Dec 2025 | −39.5× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | −23.3× |
| TNGX Tango Therapeutics, Inc. compare | −15.0× |
| IOVA Iovance Biotherapeutics, Inc. compare | −14.9× |
| IRON Disc Medicine, Inc. compare | −12.1× |
| RLAY Relay Therapeutics, Inc. compare | −12.0× |
| XENE Xenon Pharmaceuticals Inc. compare | −8.5× |
| VKTX Viking Therapeutics, Inc. compare | −5.1× |
| DYN Dyne Therapeutics, Inc. compare | −4.6× |
| PBLS Parabilis Medicines, Inc. compare | 2.6× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement